Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03949764 · ClinicalTrials.gov registry record · Phase 4
The Kentucky Viral Hepatitis Treatment Study
A Phase 4 study of Hepatitis C and Opioid-Related Disorders, sponsored by Jennifer Havens.
- Completed
- Registry status
- Phase 4
- Development phase
- 374
- Enrollment target
- 1
- Study location
NCT03949764 is a Phase 4 study of Hepatitis C and Opioid-Related Disorders that has completed, run by Jennifer Havens. The registered enrollment target is 374 participants, below the 1,887-participant average among 106 other Hepatitis C trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03949764, a Phase 4 study of Hepatitis C and Opioid-Related Disorders, has completed, sponsored by Jennifer Havens.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 374 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to determine whether removing barriers (cost, insurance, specialist, abstinence) associated with accessing direct-acting antivirals (DAAs) for the treatment of HCV will impact health in Perry County, Kentucky.
Conditions Studied
Interventions
- DRUG Sofosbuvir/velpatasvir (Epclusa®)
Study Locations (1)
Kentucky
- ARH Medical Mall - Hazard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03949764
The ClinicalTrials.gov registry entry for NCT03949764 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 374 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,887-participant average among 106 other Hepatitis C trials with a reported enrollment target (80% lower). The listed sponsor is Jennifer Havens, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Sofosbuvir/velpatasvir (Epclusa®) is the first listed.
NCT03949764 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT03949764 about?
NCT03949764 is a clinical study titled "The Kentucky Viral Hepatitis Treatment Study". The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to ...
What is the current status of trial NCT03949764?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 374 participants. The study started on 2019-09-23. Estimated completion is 2025-06-30.
What conditions does trial NCT03949764 study?
This clinical trial studies the following conditions: Hepatitis C, Opioid-Related Disorders, Injection Drug Use.
What interventions are being tested in trial NCT03949764?
The interventions under investigation include: Sofosbuvir/velpatasvir (Epclusa®) (DRUG).
Who is sponsoring clinical trial NCT03949764?
This trial is sponsored by Jennifer Havens, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03949764 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
-
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
COMPLETED · Phase 4
-
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
COMPLETED · Phase 4
-
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.